DAPSONE HYPERSENSITIVITY SYNDROME: A COMPLICATION OF DAPSONE THERAPY

LAKSHMI NARASIMHA GUNTURU*1, SUNAINA V1, REDDY SANTHOSH C2, HARI KIRAN VN2
1Department of Pharmacy Practice, Annamacharya College of Pharmacy, Rajam pretty, Andhra Pradesh, India. 2Department of Pharmacy Practice, Government General Hospital, Anantapuram, Andhra Pradesh, India. Email: gunturunarasimha007@gmail.com

Received: 31 January 2021, Revised and Accepted: 21 February 2021

ABSTRACT

Dapsone is chemically sulfonamide with its leprostatic mechanism used in the treatment of Hansen’s disease. It is one of the safest drugs in leprosy patients. Apart from its safety, it is associated with various adverse effects such as hemolytic anemia, allergic dermatitis, agranulocytosis, methaemoglobinemia, and dapsone hypersensitivity syndrome (DHS). DHS typically presents with fever, skin eruptions, jaundice, and hepatomegaly (organ involvement). We present a case of 35-year-old female attended to Government General Hospital with complaints of fever, skin rashes, and yellowish discoloration of the eyes. She had past medication history of dapsone taken for paucibacillary leprosy for 4 weeks. Her symptoms appeared after a month and become intolerable to dapsone. Laboratory investigations revealed hepatomegaly, anemic with jaundice. Based on dermatological examination, her diagnosis was confirmed as DHS. The drug was stopped and the patient was treated with drugs for the symptomatic cure. She was recovered from her condition and the multibacillary leprosy multidrug treatment regimen was continued without dapsone.

Keywords: Hansen’s disease, Dapsone hypersensitivity syndrome, Skin eruptions, Hepatomegaly.

INTRODUCTION

Dapsone (4,4-diamino-diphenyl sulphone) is used in the treatment of hypersensitivity disorders, variety of infections. It is most widely used as an anti-leprosy drug in the treatment of Hansen’s disease [1]. Common side effects associated with the dapsone include hemolytic anemia, methemoglobinemia, nausea, and jaundice, whereas severe life-threatening adverse effects include dapsone hypersensitivity syndrome (DHS) or sulfone syndrome and Toxic Epidermal Necrolysis. DHS is a hypersensitivity reaction that occurs due to Dapsone intolerance and was first reported in 1950 by Lowe and named by Allday and Barnes [2]. It was associated with fever, skin eruptions, and hemolytic anemia that progress to jaundice with systemic organ involvement like the liver. The present case report emphasizes the 35-year-old female with DHS who was on the multibacillary leprosy multidrug treatment (MB-MDT) regimen.

CASE REPORT

A 35-year-old female patient who was on an adult MB-MDT regimen for 4 weeks presented to Government General Hospital, Kadapa with complaints of yellowish discoloration of the eyes, generalized swelling all over the body with loss of appetite. Her medical history signifies that she is a known case of Hansen’s disease and has used dapsone 100 mg daily as a part of the treatment regimen for 4 weeks. During her admission after clear examination, it was found that lesions are multiple popular lesions over the body and a triad of symptoms such as fever, skin eruption, and internal organ involvement like the liver. The present case report emphasizes the 35-year-old female with DHS who was on the multibacillary leprosy multidrug treatment (MB-MDT) regimen.

OUTCOME AND FOLLOW-UP

After suspecting the condition, the patient was advised to stop dapsone and started treatment to DHS. She was prescribed with ceftriaxone injection 1 g OD, IV fluids, injection pantoprazole 40 mg OD, tablet doxycycline 100 mg OD, acetaminopen tablet 500 mg TID, and glicterine lotion, Ursodeoxycholic acid 300 mg BD. After 8 days of treatment, the patient showed significant improvement in her condition and got discharged with medications T. Amoxicillin 500 mg BD, T. Ursodeoxycholic acid 300 mg BD, T. Ondansetron 8 mg BD, and T. Acetaminophen 500 mg BD.

CONCLUSION

This case reported the rare and fatal adverse event of dapsone therapy and a careful vision is needed on the patients who are on the dapsone treatment. This work also signifies the managing of adverse drug reactions in MB-MDT for the successful establishment of an anti-leprosy regimen. Early withdrawal of the causative agent is essential to prevent the progression of the reaction. Hence, awareness should be created among the people using the MB-MDT regarding their use and side effects of drugs which would also be helpful as a part of the pharmacovigilance program.
ACKNOWLEDGMENT
None.

CONFLICTS OF INTEREST
Nil.

FUNDING
None.

REFERENCES
1. Vinod KV, Arun K, Dutta TK. Dapsone hypersensitivity syndrome: A rare life threatening complication of dapsone therapy. J Pharmacol Pharmacother 2013;4:158-60.
2. Grace M. An unusual case of dapsone syndrome. Indian Dermatol Online J 2011;2:88-90.
3. Swetha S, Vyshnavi P, Geethanjali K, Nedamanuru K. A Case Report on Dapsone Syndrome in Leprosy Patient, EC Pulmonology and Respiratory Medicine; 2018. p. 322-4.
4. Lakshmi R, Liniya S, Vijayalakshmi S. Dapsone induced hypersensitivity syndrome-a case report. Int J Pharm Pharm Sci 2015;7:585-7.
5. Kesari HV, Gawali UP, Agharia MA. Dapsone hypersensitivity syndrome: A potentially fatal condition-case report. J Clin Diagn Res 2017;11:1-3.
6. Sinha P, Das P, Sharma N, Bhattcharjee S. A case of Hansen’s disease presenting with sulfone syndrome and hemolytic anemia. J Mar Med Soc 2018;20:67-9.
7. Guragain S, Upadhayay N, Bhattarai BM. Adverse reactions in leprosy patients who underwent dapsone multdrug therapy: A retrospective study. Clin Pharmacol 2017;9:73-8.

Fig. 1: Eyes of patient revealing yellowish color